Our Bureau, Mumbai Ipca Laboratories and Heritage Pharmaceuticals Inc have launched Propranolol tablets in US after receiving necessary approval from US FDA for manufacture and marketing Propranolol HCI tablets in 10, 20, 40, 60 and 80 mg strength. These tablets have multiple cardiovascular related indications, including the management of hypertension, treatment of angina and a trial fibrillation. As per the IMS Health report Propranolol had US brand and generic sales of approximately $25 million for the year ended December 2007. Ipca and Heritage have entered into a strategic alliance under which Ipca will manufacture and Heritage will market this formulation in the US healthcare system using Ipca's DMF approved...
[read full story]
Your Web Site
